

Ossian Health Economics and Communications

Bäumleingasse 20

4051

Basel

Switzerland

08 July 2020

To whom it may concern

Re submission of manuscript "Cost-effectiveness and budget impact of lutetium [¹⁷⁷Lu] oxodotreotide versus everolimus in patients with gastroenteropancreatic neuroendocrine tumors in Sweden and Norway"

No new clinical trial or patient level data were generated as part of this analysis. All data used in the analysis have been previously published, therefore institutional review board approval was not required.

Yours Faithfully

Dr Jayne Palmer

Ossian Health Economics and Communications